Philippe van de Borne

Cardiology and Cardiovascular Medicine · 2013–2014

A researcher in the Science corpus: 3 papers; trusts 2 researchers and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

Whom Philippe van de Borne trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. P. Ridker
  2. Barry R. Davis

Papers from Philippe van de Borne's perspective

Ordered by how strongly the researchers Philippe van de Borne trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. (The Lancet)
  2. Prognostic Value of Ambulatory and Home Blood Pressures Compared With Office Blood Pressure in the General Population: Follow-Up Results From the Pressioni Arteriose Monitorate e Loro Associazioni… (Circulation)
  3. Assessing kidney function--measured and estimated glomerular filtration rate. (New England Journal of Medicine)
  4. Morbidity and Mortality After Stroke, Eprosartan Compared With Nitrendipine for Secondary Prevention: Principal Results of a Prospective Randomized Controlled Study (MOSES) (Stroke)
  5. Effect of continuous positive airway pressure on the incidence of hypertension and cardiovascular events in nonsleepy patients with obstructive sleep apnea: a randomized controlled trial. (Journal of the American Medical Association (JAMA))
  6. Interventions used to improve control of blood pressure in patients with hypertension. (Cochrane Database of Systematic Reviews)
  7. Neural Control of Renal Function (Comprehensive Physiology)
  8. Carotid intima-media thickness and presence or absence of plaque improves prediction of coronary heart disease risk in the Atherosclerosis Risk in Communities (ARIC) study (Journal of the American College of Cardiology)
  9. Cardiovascular sequelae of preeclampsia/eclampsia: a systematic review and meta-analyses. (American Heart Journal)
  10. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. (The Lancet)

Their papers